The Oncology Institute (TOI)
Manages community cancer care with patient services, specialty pharmacy, and clinical trials.
$5.13
At close−1.26 (−19.72%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82 | 86 | 95 | 99 | 100 | 100 | 104 | 120 | 137 | 142 | 147 | 161 |
| Cost of revenue | 66 | 71 | 83 | 86 | 86 | 86 | 87 | 102 | 118 | 119 | 126 | 0 |
| Gross profit | 16 | 14 | 12 | 13 | 14 | 15 | 17 | 18 | 19 | 23 | 22 | 0 |
| 30 | 30 | 30 | 29 | 28 | 27 | 27 | 29 | 27 | 30 | 28 | 166 | |
| Selling, general & administrative | 0 | 0 | 0 | 0 | 0 | 25 | 25 | 0 | 25 | 28 | 28 | 30 |
| Other expenses | 30 | 30 | 30 | 29 | 28 | 2 | 2 | 29 | 2 | 2 | 0 | 136 |
| Operating income | −14 | −15 | −18 | −16 | −14 | −12 | −10 | −11 | −8 | −7 | −7 | −5 |
| −3 | −4 | −2 | 1 | −2 | −1 | −10 | −6 | −8 | −1 | 4 | −5 | |
| Interest income | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 3 | 2 | 2 | 2 | 2 | 1 | 6 | 2 | 2 | 2 | 2 | 2 |
| Other non-operating income | 0 | 0 | 0 | −3 | 0 | 0 | 4 | 4 | 7 | −1 | −6 | 0 |
| Income before tax | −17 | −19 | −20 | −15 | −16 | −13 | −20 | −17 | −17 | −8 | −2 | −10 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −17 | −19 | −20 | −15 | −16 | −13 | −20 | −17 | −17 | −8 | −2 | −10 |
| Net income | −17 | −19 | −20 | −15 | −16 | −13 | −20 | −17 | −17 | −8 | −2 | −10 |
| EPS, basic | −$0.19 | −$0.21 | −$0.22 | −$0.17 | −$0.18 | −$0.14 | −$0.21 | −$0.15 | −$0.14 | −$0.04 | −$0.02 | −$0.08 |
| EPS, diluted | −$0.19 | −$0.21 | −$0.22 | −$0.17 | −$0.18 | −$0.14 | −$0.21 | −$0.15 | −$0.14 | −$0.04 | −$0.02 | −$0.08 |
| Weighted average shares, basic | 73 | 73 | 74 | 75 | 76 | 76 | 77 | 932 | 975 | 1,015 | 1,018 | 1,030 |
| Weighted average shares, diluted | 73 | 73 | 74 | 75 | 76 | 76 | 77 | 932 | 975 | 1,015 | 1,018 | 1,030 |
| EBITDA | −12 | −14 | −16 | −12 | −12 | −10 | −12 | −13 | −13 | −4 | 1 | −3 |
| Depreciation & amortization | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBIT | −14 | −15 | −18 | −13 | −14 | −12 | −14 | −15 | −15 | −6 | −1 | 0 |
